article.page.titleprefix Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
Date
2023-04-24
Journal Title
Journal ISSN
Volume Title
Publisher
Clinical Microbiology and Infection
Abstract
Objectives
The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients.
Methods
We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines.
Results
Among 1215 patients (median age, 73.0 years; interquartile range, 57.0–84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32–0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26–0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25–0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37–0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12–0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38–0.67]), independent of age, comorbidities, and vaccination status.
Discussion
Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics.
Description
Open Access, Published by Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2022.12.020, Guillaume Beraud 1, *, Laura Bouetard 2, 3, Rok Civljak 4, 5 , Jocelyn Michon 6, Necla Tulek 7,Sophie Lejeune 8 , Romain Millot 1, Aurelie Garchet-Beaudron 9, Maeva Lefebvre 10, 11,Petar Velikov 12, Benjamin Festou 13, Sophie Abgrall 2, 3 , Ivan K. Lizatovic 4,
Aurelie Baldolli 6 , Huseyin Esmer 7, Sophie Blanchi 9, Gabrielle Froidevaux 10,Nikol Kapincheva 12, Jean-François Faucher 13, 14, Mario Duvnjak 15, 16, Elçin Afsar 17,Luka Svitek 15, 16, Saliha Yarimoglu 18, Rafet Yarimoglu 18, Cecile Janssen 19 ,Olivier Epaulard 8, on behalf of EVASG (ESCMID vaccination study group)
1)
Infectious Disease Department, University Hospital of Poitiers, Poitiers, France
2)
Assistance Publique des Hôpitaux de Paris, Hôpital Antoine Béclère, Service de Médecine Interne, Clamart, France
3)
Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, INSERM U1018, Centre de Recherche en Épidémiologie et Santé des Populations, Le Kremlin-Bicêtre, France
4)
University Hospital for Infectious Diseases ‘Dr. Fran Mihaljevic’ Zagreb, Croatia
5)
University of Zagreb School of Medicine, Zagreb, Croatia
6)
Department of Infectious Diseases, University Hospital of Caen, Caen, France
7)
Atilim University, Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
8)
Infectious Diseases, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
9)
Infectious Diseases Department, Centre Hospitalier, Le Mans, France
10)
Infectious Diseases Department, Centre for Prevention of Infectious and Transmissible Diseases, Centre Hospitalier Universitaire de Nantes, Nantes, France
11)
INSERM Centre d'Investigation Clinique 1413 Nantes University, Nantes, France
12)
Infectious Diseases Hospital ‘Prof. Ivan Kirov’, Medical University of Sofia, Sofia, Bulgaria
13)
Centre Hospitalier Universitaire de Limoges, Department of Infectious Diseases and Tropical Medicine, Limoges, France
14)
INSERM U1094, Limoges, France
15)
Clinic for Infectious Diseases, University Hospital Centre Osijek, Osijek, Croatia
16)
Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
17)
Atılım University, Vocational School of Health Services, Ankara, Turkey
18)
Karaman Training and Research Hospital, Karaman, Turkey
19)
Infectious Disease Unit, Centre Hospitalier Annecy Genevois, Annecy, France
Keywords
Breakthrough infection, Omicron, SARS-CoV-2, Severity, Vaccine
Citation
http://hdl.handle.net/20.500.14411/1915